Trial NCT02757391

View at ClinicalTrials.gov 
Org. Study IDs: 2015-0152
Secondary IDs: 2015-0152 NCI-2016-01058

Last trial update was posted on 2020-10-30

MeSH Interventions

Aldesleukin Cyclophosphamide Immunologic Factors Immunomodulating Agents Interleukin-2 Pembrolizumab

MeSH Conditions

Adenocarcinoma Carcinoma Cholangiocarcinoma Colorectal Neoplasms Esophageal Neoplasms Stomach Neoplasms

Other Conditions

Colorectal Adenocarcinoma Metastatic Cholangiocarcinoma Metastatic Colorectal Carcinoma Metastatic Digestive System Carcinoma Metastatic Esophageal Carcinoma Metastatic Gastric Carcinoma Metastatic Pancreatic Adenocarcinoma Stage IV Colorectal Cancer AJCC v7 Stage IV Esophageal Cancer AJCC v7 Stage IV Gastric Cancer AJCC v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Stage IVA Colorectal Cancer AJCC v7 Stage IVB Colorectal Cancer AJCC v7

Stopping Reasons

Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID